NASDAQ:DXCMDexCom Stock Price, Forecast & News

DexCom's stock was trading at $252.42 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, DXCM shares have increased by 61.4% and is now trading at $407.35. View which stocks have been most impacted by Coronavirus.

21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 5 hold ratings and 16 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for DexCom.

DexCom is scheduled to release its next quarterly earnings announcement on Tuesday, July 28th 2020. View our earnings forecast for DexCom.

DexCom will be holding an earnings conference call on Tuesday, July 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

DexCom, Inc. (NASDAQ:DXCM) posted its quarterly earnings data on Tuesday, April, 28th. The medical device company reported $0.44 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.15 by $0.29. The medical device company earned $405.10 million during the quarter, compared to the consensus estimate of $358.34 million. DexCom had a return on equity of 26.44% and a net margin of 9.24%. The company's revenue was up 44.4% on a year-over-year basis. During the same period in the prior year, the company posted ($0.05) EPS. View DexCom's earnings history.

21 analysts have issued 1 year price objectives for DexCom's shares. Their forecasts range from $190.00 to $500.00. On average, they expect DexCom's stock price to reach $347.65 in the next twelve months. This suggests that the stock has a possible downside of 14.7%. View analysts' price targets for DexCom.

News coverage about DXCM stock has been trending negative this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. DexCom earned a coverage optimism score of -2.0 on InfoTrie's scale. They also assigned press coverage about the medical device company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about DexCom.

DexCom saw a decrease in short interest in the month of June. As of June 15th, there was short interest totaling 4,770,000 shares, a decrease of 16.8% from the May 31st total of 5,730,000 shares. Based on an average daily trading volume, of 1,920,000 shares, the short-interest ratio is currently 2.5 days. Currently, 5.3% of the shares of the stock are sold short. View DexCom's Current Options Chain.

Some companies that are related to DexCom include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Intuitive Surgical (ISRG), Becton Dickinson and (BDX), Boston Scientific (BSX), Baxter International (BAX), Edwards Lifesciences (EW), IDEXX Laboratories (IDXX), ResMed (RMD), Teleflex (TFX), Hologic (HOLX), Steris (STE), Masimo (MASI) and Insulet (PODD). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other DexCom investors own include NVIDIA (NVDA), Alibaba Group (BABA), Paypal (PYPL), Netflix (NFLX), Advanced Micro Devices (AMD), salesforce.com (CRM), Vertex Pharmaceuticals (VRTX), Adobe (ADBE), ServiceNow (NOW) and Shopify (SHOP).

DexCom trades on the NASDAQ under the ticker symbol "DXCM."

Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of DXCM stock can currently be purchased for approximately $407.35.

DexCom has a market capitalization of $37.62 billion and generates $1.48 billion in revenue each year. The medical device company earns $101.10 million in net income (profit) each year or $1.84 on an earnings per share basis. DexCom employs 3,900 workers across the globe.

The official website for DexCom is www.dexcom.com.

DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]